Preparing to Enter the Chinese Market
First written in FY2024-Q3. 3 of 5 entries say "Advanced", first in FY2025-H1. Latest entry: 2026-07-22.
No other company in this theme has enough history to compare yet.
- 2026-07-22AdvancedBusiness Alliances
「We are preparing to conduct an additional trial in China.」
For expansion into the Chinese market, the company presented preparations for an additional trial and a plan for the trial to be conducted by another development partner with strengths in the Chinese market. - FY2026AdvancedAnnual report
「In March 2025, the company entered into a license agreement with Beijing Yijie Pharmaceutical Technology Co., Ltd. relating to TLG-001 in China.」
Regarding entry into the Chinese market, progress advanced from the Eye Valley base and the agreement with Shenyang Xingqi to a TLG-001 China licensing agreement with Beijing Yijie and the conduct of clinical trials in China. - FY2025-H1AdvancedAnnual report
「In business development, entry into the high-potential Chinese market made rapid progress. In addition to being the first Japanese company to open an office in Eye Valley in Wenzhou, Zhejiang Province, the center of China's national-level myopia research, and the appointment of our representative Tsubota Kazuo (坪田 一男) as a visiting professor of ophthalmology at Wenzhou Medical University, in September we concluded a patent licensing agreement covering specific regions with Shenyang Xingqi Pharmaceutical Co., Ltd., a major Chinese ophthalmic pharmaceutical company. We believe this will enable us to make treatments based on our patents widely available in China.」
Regarding entry into the Chinese market, the company reported specific progress, including the opening of an office in Eye Valley, the appointment of a visiting professor of ophthalmology at Wenzhou Medical University, and the conclusion of a patent licensing agreement covering specific regions. - FY2024ReframedAnnual report
「To continue joint research and development with partner companies, the company is strengthening its basic research while promoting the overseas rollout of its pipelines currently deployed in Japan」
Rather than the specifically named entry into the Chinese market in the previous filing, the description has been broadened to the overseas rollout of domestic pipelines. - FY2024-Q3First statedAnnual report
「Business activities aimed at entering the high-potential Chinese market」
The company identified business activities aimed at entering the Chinese market as a standalone area of focus for the first time. No specific milestones, such as the conclusion of a partnership or completion of market entry, were indicated.